Thursday, July 18, 2013

Sihuan Pharmaceutical Secures SFDA Approval for conducting clinical studies on Anaprazole Sodium - A novel PPI

Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic of China. Anaprazole Sodium is the fifth Category 1 innovative drug in respect of which the Company has received approval for Clinical Studies, applications for patents have been made in China, the United States, Japan and Europe.
Anaprazole Sodium is a new generation of proton pump inhibitors (“PPIs”) which treats ulcers quickly and efficiently by inhibiting gastric acid secretion and eradicating Helicobacter pylori. Preclinical studies have shown that the new drug covalently binds to proton pump, thus providing substantially stronger and longer inhibitory effects when compared to other PPI drugs currently available in the market. Therefore, it can effectively treat various gastric acid diseases,and is safer and possess the properties of rapid onset, stronger and longer duration of acid inhibition.

Further to getting clinical trial approval for Benapenem and Imigliptin Hydrochloride, our Company has once again succeeded in having clinical approval for Anaprazole Sodium, another innovative drug, demonstrating the continuous enhancement of its R&D capabilities.

Anaprazole Sodium will offer physicians and patients better treatment options after its launch, and will vigorously drive the development of the Company in the field of digestive system. This follows the launch of Roxatidine, an exclusive first-to-market generic drug this year. This will further consolidate the diversified product lines of the Company and drive its sustainable growth. Looking into the future, we will continue to bring our strong research and development capabilities into full play by developing more innovative drugs, so as to further inject new momentum into the Company’s development.

Enter your email address:

Delivered by FeedBurner

No comments:

Post a Comment